AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines

Novel and effective chemotherapeutic agents are needed to improve cancer treatment. Epidrugs are currently used for cancer therapy but also exhibit toxicity. Targeting the epigenetic apparatus with bioproducts may aid cancer prevention and treatment. To determine whether the lipoprotein marine extract AntiGan shows epigenetic and antitumor effects, cultured HepG2 (hepatocellular carcinoma) and HCT116 (colorectal carcinoma) cell lines were treated with AntiGan (10, 50, 100, and to 500 mu g/mL) for 24 h, 48 h, and 72 h. AntiGan (10 mu g/mL) reduced cell viability after 48 h and increased Bax expression; AntiGan (10 and 50 mu g/mL) increased caspase-3 immunoreactivity in HepG2 and HCT116 cells. AntiGan (10 and 50 mu g/mL) attenuated COX-2 and IL-17 expression in both cell lines. AntiGan (10 mu g/mL) increased 5mC levels in both cell types and reduced DNMT1 and DNMT3a expression in these cells. AntiGan (10 and 50 mu g/mL) promoted DNMT3a immunoreactivity and reduced SIRT1 mRNA expression in both cell types. In HCT116 cells treated with AntiGan (10 mu g/mL), SIRT1 immunoreactivity localized to nuclei and the cytoplasm; AntiGan (50 mu g/mL) increased cytoplasmic SIRT1 localization in HCT116 cells. AntiGan is a novel antitumoral bioproduct with epigenetic properties (epinutraceutical) for treating liver and colorectal cancer.

Automated summary

This study investigates the effects of AntiGan, a novel antitumoral bioproduct, on liver and colorectal cancer cells. AntiGan showed antitumor effects, increased Bax expression, and decreased cell viability in both cell lines. It also exhibited epigenetic properties, affecting the expression of COX-2, IL-17, DNMTs, and SIRT1.